Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $5.1 million.

  • Nurix Therapeutics' Capital Expenditures rose 14375.3% to $5.1 million in Q4 2025 from the same period last year, while for Nov 2025 it was $14.0 million, marking a year-over-year increase of 5099.75%. This contributed to the annual value of $14.0 million for FY2025, which is 5099.75% up from last year.
  • According to the latest figures from Q4 2025, Nurix Therapeutics' Capital Expenditures is $5.1 million, which was up 14375.3% from $2.7 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Capital Expenditures registered a high of $5.1 million during Q4 2025, and its lowest value of $843000.0 during Q1 2021.
  • Its 5-year average for Capital Expenditures is $2.5 million, with a median of $2.5 million in 2022.
  • Per our database at Business Quant, Nurix Therapeutics' Capital Expenditures soared by 31186.24% in 2022 and then crashed by 6127.64% in 2023.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Capital Expenditures stood at $862000.0 in 2021, then skyrocketed by 197.56% to $2.6 million in 2022, then rose by 0.78% to $2.6 million in 2023, then decreased by 18.57% to $2.1 million in 2024, then surged by 143.75% to $5.1 million in 2025.
  • Its Capital Expenditures stands at $5.1 million for Q4 2025, versus $2.7 million for Q3 2025 and $2.7 million for Q2 2025.